Venetoclax: evidence to date and clinical potential.
Juárez-Salcedo, Luis Miguel; Desai, Viraj; Dalia, Samir.
; 8: 212574, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31645879
Biomedical research in france and brazil: an analysis of significant differences and ethical issues
Venetoclax: A new wave in hematooncology.
Venetoclax: Targeting BCL2 in Hematological Cancers.
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.